Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.3K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.3K
T Cell Types and Functions01:24

T Cell Types and Functions

1.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering immune tolerance for AAV gene therapy: The Norse way.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Beta cell microRNAs function as molecular hubs of type 1 diabetes pathogenesis and as biomarkers of diabetes risk.

Diabetologia·2026
Same author

Transient prophylactic immunosuppression with abatacept or dasatinib prevents immune responses in AAV gene transfer.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Soluble LAG-3 Identifies a Dynamic Early T Cell Activation Window in self-reactivity, Type 1 Diabetes, and Broader Immune Responses.

bioRxiv : the preprint server for biology·2026
Same author

Enhancing AAV9-UFμDys1 Gene Therapy Efficacy Through Immunosuppression in Mice with Pre-Existing Immunity and Enabling Redosing Strategies for Duchenne Muscular Dystrophy.

Human gene therapy·2025
Same author

CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs.

Frontiers in immunology·2025

Related Experiment Video

Updated: Dec 11, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.1K

Regulatory T cell therapy: Current and future design perspectives.

Jyoti Rana1, Moanaro Biswas1

  • 1Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.

Cellular Immunology
|August 22, 2020
PubMed
Summary

Engineered regulatory T cells (Tregs) offer promising cellular therapies for immune disorders. Enhancing chimeric antigen receptor (CAR) Treg design is crucial for improving their potency and persistence in clinical applications.

Keywords:
Antigen specific T cellsAutoimmune diseasesChimeric antigen receptorImmune toleranceRegulatory T cellsTransgenic TCRscFv

More Related Videos

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.1K
Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

24.7K

Related Experiment Videos

Last Updated: Dec 11, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.1K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.1K
Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells
14:23

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

24.7K

Area of Science:

  • Immunology and Cell Therapy
  • Transplantation and Autoimmune Disease Research

Background:

  • Regulatory T cells (Tregs) are vital for maintaining immune homeostasis by suppressing immune responses.
  • Cellular therapies utilizing Tregs show potential in treating transplantation rejection and autoimmune diseases.
  • Current Treg-based therapies face limitations in widespread clinical application due to specificity and efficacy challenges.

Purpose of the Study:

  • To review existing Treg-based therapies, highlighting their clinical advantages and limitations.
  • To explore strategies for enhancing the design of engineered chimeric antigen receptor (CAR) Tregs.
  • To discuss the adaptation of CAR T cell design principles for CAR Treg optimization.

Main Methods:

  • Review of current Treg-based therapeutic approaches and their clinical trial outcomes.
  • Examination of design strategies applicable to CAR T cells for potential CAR Treg enhancement.
  • Analysis of factors influencing CAR Treg potency, persistence, and specificity.

Main Results:

  • Existing Treg therapies demonstrate preclinical and clinical promise but require further optimization.
  • Several CAR T cell design principles, including co-stimulatory signaling domains and scFv affinity, can be adapted for CAR Tregs.
  • Co-expression of accessory molecules may further improve CAR Treg function.

Conclusions:

  • Improving the design of engineered CAR Tregs is essential for advancing their clinical utility.
  • Tailoring CAR Treg design to specific diseases is critical for maximizing therapeutic efficacy.
  • Further research into CAR Treg engineering holds significant potential for treating immune-mediated conditions.